

**IX BIOPHARMA LTD.**  
(Company Registration Number 200405621W)  
(Incorporated in the Republic of Singapore)

---

**PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN S\$6,000,000  
– COMPLETION OF PROPOSED PLACEMENT**

---

The Board of Directors of iX Biopharma Ltd. (the “**Company**”) (the “**Board**”) refers to its announcements dated 12 February 2026, 13 February 2026 and 19 February 2026 in relation to the Proposed Placement (collectively, the “**Announcements**”).

Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Announcements.

Further to the Announcements, the Board is pleased to announce that the Proposed Placement has been completed on 24 February 2026, pursuant to which 75,800,000 New Shares were allotted and issued by the Company on the terms and subject to the conditions as set out in the Placement Agreement. Following the completion of the Proposed Placement, the total number of issued Shares of the Company has increased from 960,495,895 Shares to 1,036,295,895 Shares. The New Shares rank *pari passu* with the existing Shares of the Company.

The New Shares are expected to be listed and quoted on the Catalist of SGX-ST on or around 26 February 2026 and trading of the New Shares will commence with effect from 9.00 a.m. on the same date.

By Order of the Board  
**IX BIOPHARMA LTD.**

Eddy Lee Yip Hang  
Chairman & CEO

24 February 2026

---

*This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.*

**IMPORTANT NOTICE**

THE NEW SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, (THE “**SECURITIES ACT**”) OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION, AND THE NEW SHARES MAY NOT BE

OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.